Friends! In this video, I'm going to analyze CRM Stock & FICO stock
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 28 Apr 2026, 22:21 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:24 UTC
AI-generated source summary
The analysis focuses on two stocks, FICO and Salesforce (CRM), highlighting their recent price performance and future outlook. FICO is presented as potentially undervalued with strong future growth prospects, while Salesforce is depicted as having missed its guidance and facing management issues, making it a less attractive investment. The analyst also touches upon the broader market trend of AI infrastructure stocks booming and discusses the importance of proper valuation and company fundamentals. For FICO, the target price is projected at $2279.43 based on a PE ratio of 24 and anticipated earnings growth. Salesforce, on the other hand, is seen as facing headwinds due to missed guidance and leadership concerns, leading to a bearish outlook. The company's overpayment for acquisitions and the shift towards a subscription-based revenue model are noted as potential challenges.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.